Navigation Links
EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
Date:3/3/2008

Online feedback platform will remain open until March 21, 2008

HOUSTON, March 3 /PRNewswire-USNewswire/ -- Using the same process as government agencies when implementing new policies, a national alliance of scientists, public health leaders, and community representatives today called for public comment on a series of proposals designed to eliminate continued disparities in U.S. clinical trials.

As part of the four year initiative, Eliminating Disparities in Clinical Trials (EDICT), a project jointly conducted by Baylor College of Medicine's Chronic Disease Prevention and Control Research Center and the Intercultural Cancer Council, the alliance created a new Web-based portal so policy makers, patient advocates, research scientists and industry members can review the proposals developed to improve clinical trials patient recruitment and retention in medical research studies. The public comment period closes on March 21, 2008.

On April 1, EDICT will issue its final policy recommendations in Washington, DC.

"A variety of systemic, cultural and psychosocial barriers prevent participation by underrepresented populations, including women, adolescents, older adults, racial and ethnic minorities, those with disabilities, in rural areas and others," said Armin D. Weinberg, Ph.D., Director of Baylor College of Medicine's Chronic Disease Prevention and Control Research Center and EDICT's Principal Investigator.

More than 300 representatives of public, private and non-profit stakeholders catalogued the most significant barriers to participation, examined current policies related to clinical trials, identified opportunities for policy change that would address those barriers, and developed practical and realizable policy solutions to clinical trial disparities at the federal, state and institutional levels in the public, private and non-profit sectors.

"Our policy research has demonstrated the importance of involving the broadest possible set of stakeholders as part of this process. To date, we had input from across all stakeholder groups involved in clinical trials. We are now seeking input from the public at large. We hope that interested individuals and those representing concerned populations will review the policy change recommendations and provide feedback," Weinberg said.

To review the policy recommendations and provide feedback, go to http://www.bcm.edu/edict/policyreview.

EDICT Credo:

-- Everyone should have the opportunity and necessary support to participate voluntarily in clinical trials for which they are eligible.

-- Participants and researchers should understand the benefits of diversity in clinical trials.

-- Results from clinical research should benefit the participants' communities and society at large.

The EDICT (Eliminating Disparities in Clinical Trials) Project was created by Baylor College of Medicine's Chronic Disease Prevention and Control Research Center with the Intercultural Cancer Council and supported by an unrestricted educational grant from Genentech, Inc.


'/>"/>
SOURCE EDICT
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Simple Test Accurately Predicts Risk of Serious Jaundice in Newborns
2. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
3. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
4. DNA Test Predicts Harmful Effects of Cancer Drug
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
7. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
8. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
9. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
10. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
11. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The report forecasts the global optical ... period 2016-2020. The report covers the present scenario ... 2016-2020. To calculate the market size, the report considers the revenue ...
(Date:12/9/2016)... 9, 2016 Mitsubishi Tanabe Pharma Corporation (Head ... Director, CEO: Dr. Masayuki Mitsuka ) has presented ... given edaravone intravenously in 10-14 day cycles for 48 ... the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were ... ALS/MND in Dublin, Ireland . ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... 10, 2016 , ... "TransPanel Volume 2 is a package of fading panel ... - CEO of Pixel Film Studios. , TransPanel Volume 2 is a set ... set of versatile transitions features presets with up to 4 panels with complementary line ...
(Date:12/9/2016)... ... 2016 , ... Groth Family Insurance, a Washington-based firm offering ... a charity drive to support the family of Cindy Hendrickson, a local mother ... On October 29th of this year, Cindy Hendrickson swerved to avoid an oncoming ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
Breaking Medicine News(10 mins):